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NOTCH SIGNALING INHIBITED BY IKAROS1 IN HUMAN T-CELL ACUTE
LYMPHOBLASTIC LEUKEMIA
Camille Whittington Graham, B.S.
Thesis Advisor: Patrick Zweidler-McKay, M.D., Ph.D.
The highly conserved Notch signaling pathway regulates cell growth, differentiation,
survival and apoptosis. In hematopoiesis, Notch signaling drives commitment to the T-cell fate
and promotes differentiation, T-cell receptor signaling and immune function. In T-cells, Notch
signaling is oncogenic when constitutively active, promoting proliferation and survival while
inhibiting differentiation. The majority of patients with T-cell acute lymphoblastic leukemia (TALL) have activating Notch mutations. Similarly, Notch activation is present in more than 75%
of murine T-ALL models. In murine T-ALL, loss of Ikaros, a zinc finger transcriptional regulator,
leads to disrupted differentiation and also cooperates with activated Notch signaling to
promote T-ALL. Loss of Ikaros function most frequently results from alternative RNA splicing,
which leads to expression of non-DNA-binding isoforms. In murine T-ALL, Notch and Ikaros
are reciprocally regulated. Specifically, constitutive Notch3 activation promotes expression of
non-DNA-binding Ikaros isoforms in vivo, leading to loss of Ikaros function. Additionally, Ikaros
regulates Notch by competing for binding sites in the promoter regions of Notch target genes,
Hes1 and pTα.
To determine whether this reciprocal regulation of Notch and Ikaros occurs in human
T-ALL, we expressed active intracellular Notch receptors in human T-ALL cell lines and
showed that Notch activation does not significantly increase the expression of non-DNAbinding Ikaros isoforms. While Notch activation has little effect on the pattern of Ikaros isoform
expression in human T-ALL cell lines, Ikaros exerts a repressive effect on Notch signaling,
similar to the Notch repression described in murine T-ALLs. Specifically, we demonstrated that
Ikaros overexpression inhibits growth of human T-ALLs and that Ikaros downregulates
expression of Notch target genes Hes1 and Hes5 at the transcriptional level. Interestingly,
Ikaros inhibits growth more effectively in the cell lines with stronger Notch activation. In
addition, Ikaros was shown to inhibit the Notch target gene Hes1 in both Notch dependent and
independent manners. These data support the hypothesis that disruption of Ikaros contributes
to proliferation of human T-ALL through de-repression of Notch signaling. In summary, we
have demonstrated that Ikaros represses Notch signaling in human T-ALL.

Abstract
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Chapter 1: Introduction
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Notch Signaling
The evolutionarily conserved Notch signaling pathway has been extensively
characterized in many human systems as well as murine models. Notch signaling controls
many cellular functions including differentiation, growth, proliferation and survival in a cell-type
specific and context-dependent manner. In T-cell progenitors, varying levels of Notch
activation throughout development drive cell-fate decisions and promote T-cell maturity.
However, dysregulation of Notch signaling is leukemogenic in T-cells.
In the canonical Notch signaling pathway, intercellular interactions mediated by Notch
ligands and receptors drive transcription of target genes through a CBF/RBP-Jκ, Suppressor
of Hairless, and LAG-1 (CSL)-dependent mechanism. In humans, there are five Notch ligands.
Two ligands are from the Serrate/Jagged family (JAG1 and JAG2) and three are from the
Delta-like family (DLL1, DLL3, DLL4). Notch ligands are single-pass transmembrane integral
proteins with tandem EGF-like repeats in the extracellular domain that mediate interaction with
Notch receptors (1). There are four Notch receptors, homologs referred to as Notch1, Notch2,
Notch3 and Notch4. These receptors are single-pass transmembrane integral proteins
composed of an intracellular and extracellular domain linked by a heterodimerization (HD)
domain. The extracellular domain has N-terminal tandem EGF-like repeats and a negative
regulatory region that lies closer to the cell surface. In the negative regulatory region are three
Lin12/Notch repeats and the HD domain. Cleavage sites S2 and S3, located near the
transmembrane domain, release the intracellular domain of Notch (ICN) upon ligand binding
and the action of ADAM metalloproteases and γ-secretase. The negative regulatory region
prevents ligand-independent activation of Notch signaling by sequestering the S2 cleavage
site (2). The S3 cleavage site is located in the transmembrane domain and is susceptible to
cleavage by γ-secretase, while the S2 site is susceptible to cleavage by ADAM
metalloproteases. C-terminal to the transmembrane domain is the ICN that consists of an
RBPJ-associated molecule (RAM) domain, seven ankyrin repeats, a transcription activating
domain (TAD) and a PEST domain (3). Notch3 and Notch4, have less distinct RAM or TAD
compared to Notch1 and Notch2, leading to decreased CSL binding and transactivation of
target genes. Indeed experimentally Notch3 and Notch4 are less potent at inducing Notch
signaling. ICN is depicted in Figure 1A.
When Notch signaling is inactive, a CSL-corepressor complex bound to the promoter
region of Notch target genes inhibits transcription (4). Corepressors include KyoT2,
MINT/SHARP, Hairless, and histone deacetylases (HDAC) (5, 6). This CSL-corepressor
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complex binds the following core sequence (underlined) in the Hes1 gene: 5’TGGGAAAGAAAGTTTGGGAA-3’ (7).
Ligand binding activates Notch signaling through a series of cleavage steps that
release ICN (8). ICN translocates to the nucleus, where it cooperates with Mastermind (MAM)
to disrupt the repressor complex and recruits CSL and other coactivators to drive transcription
of CSL-dependent Notch target genes. These genes include the Hairy/enhancer of split (HES)
family, HES-related repressor (HERP, HRT, HEY) family, Deltex and others. Notch signaling is
turned off through the action of the E3 ubiquitin ligase, FBXW7, which recognizes the PEST
domain and targets ICN for proteosomal degradation (9). This Notch signaling pathway is
depicted in Figure 1B.
Notch signaling is also able to regulate gene expression via CSL-independent
mechanisms. One important CSL-independent Notch target gene in regulation of
hematopoiesis is pTα (10, 11).
A.
B.

Figure 1: Notch signaling (A) Notch receptor ICN1 schematic showing the domains of the
receptor. EGF, epidermal growth factor-like repeats; LNR, Lin12/Notch repeats; T,
transmembrane domain; R, RBP-Jκ associated module; ANK, ankyrin repeats; TAD,
transcription activation domain; P, domain rich in proline, glutamate, serine and threonine
that regulates proteolytic cleavage by the proteasome. (B) Diagram of the Notch signaling
pathway showing Notch ligands, receptors, corepressors (CoR), coactivators (CoA), and
Notch target genes (Deltex, Hes1, Hes5).
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Notch signaling in T-cell development
In addition to the critical role of Notch signaling in developmental processes including
neurogenesis and vasculogenesis, Notch signaling regulates hematopoiesis, the process in
which all cellular blood components are derived from hematopoietic stem cells (HSCs). In
hematopoiesis, the major role for Notch signaling is in commitment to the T-cell fate and
promotion of differentiation, TCR signaling, and immune function. Notch signaling directs the
HSCs to differentiate into either a common lymphoid precursor cell (CLP) or a common
myeloid precursor cell (CMP). The CLP differentiates into T-cells, B-cells and natural killer
(NK) cells. T-cell subsets, including helper, cytotoxic and regulatory T-cells, develop in the
thymus from the T-cell precursor (12). Notch signaling via Notch1 drives commitment to the Tcell fate at the expense of B-cells (13) in a CSL-dependent manner (14). Notch1 expression
levels are modulated during T-cell development, during which a T-cell precursor passes
through a double negative (DN) stage (CD4-CD8-) and a double positive (DP) stage
(CD4+CD8+) to become a mature, single positive T-cell (CD4+ or CD8+). Double negative Tcells (CD4-CD8-) express high levels of Notch1, double positive T-cells express very low levels
of Notch1 and single positive T-cells express an intermediate level of Notch1 (15). This
modulation of Notch signaling may become dysregulated, and in T-cells, a persistent high level
of Notch signaling inhibits differentiation and promotes proliferation and survival.
Notch Signaling in T-cell acute lymphoblastic leukemia
While Notch signaling plays an important role in normal hematopoiesis, its
dysregulation is oncogenic in T-ALL (16, 17). Specifically, constitutive Notch signaling inhibits
differentiation and promotes proliferation and survival. In this way, Notch functions as an
oncogene in T-ALL. Specifically, activating Notch1 mutations are present in over 50% of T-ALL
(16). One activating Notch mutation, the t(7;9)(q34;q34.3) translocation, in which the carboxy
terminal portion of the Notch1 receptor is placed adjacent to the T-cell receptor beta (TCRβ)
gene enhancer region, results in Notch1 activation via constitutive expression of ICN1 or other
active Notch1 receptor isoforms. The activating Notch mutation occurs in less than 1% of TALL patients (17). Mutation in the HD domain, like the t(7:9), also results in ligand-independent
Notch signaling, and occurs in 20% of T-ALL (16). An additional mechanism for activating
Notch is through increased stability of ICN, as occurs with inactivation of the E3 ligase FBXW7
in 20% of T-ALL (18, 19). Mutations in the PEST domain also increase ICN stability and occur
in 15% of T-ALL (16). In summary, activating Notch mutations are present in the majority of TALL, and are thought to play a critical role in leukemogenesis (20).
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In mice, dysregulated Notch signaling in T-cell progenitors leads to aggressive
leukemia or lymphoma (21). Notch activation occurs in greater than 75% of murine T-ALL
models, and has been shown to cooperate with a number of pathways to promote
leukemogenesis. For example, Notch is activated in T-ALL derived from Ikaros-deficient mice
(22). Additionally, Notch activation cooperates with Ikaros knockout to induce T-ALL in mice
(23, 24). There are many hypotheses to explain the cooperation between Notch and Ikaros in
murine T-ALL. Ikaros may downregulate Notch signaling through interference with CSL
binding (24, 25) or through binding to the upstream regulatory elements (UREs) of Notch
target genes (26). These data suggest that the cooperation between Notch activation and loss
of Ikaros function plays a critical role in promotion of T-ALL.
Ikaros Structure and Function
Ikaros is a zinc-finger (ZNF) protein composed of seven exons, four DNA-binding
domains, and a dimerization domain. The first ZNF region is located 59 amino acids from the
amino terminus and is responsible for DNA binding (27). The second ZNF region is located at
the carboxy terminus, 245 amino acids from the first ZNF region (28). The carboxy terminal
ZNF region is the dimerization domain, required for Ikaros protein-protein interaction and
formation of DNA-binding homodimers. These Ikaros dimers have a much higher DNA-binding
affinity than Ikaros monomers. Ikaros activates transcription of its target genes through a Cterminal bipartite activation domain (27).
There are many Ikaros isoforms. Ikaros isoforms that maintain their DNA-binding
function are referred to as wild-type (WT). WT Ikaros isoforms include Ikaros human (IKH),
IK1, IK2, and IK3. IK1 is the largest murine Ikaros isoform and IK-H is the largest human
Ikaros isoform. IKH is similar to IK1 but also contains an additional 20 amino acid, N-terminal
activation domain that both activates transcription of Ikaros target genes and regulates
chromatin remodeling. Dominant-negative (dn) isoforms IK4 through IK9 are splice variants
that lack critical regions of the DNA-binding domain. These isoforms dimerize with WT Ikaros
and impair its ability to bind DNA (29, 30). The Ikaros isoforms are depicted in Figure 2.
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N-terminal ZnF

C-terminal ZnF

IK1
IK2
IK2a
IK3
IK3a
IK4
IK4a
IK5
IK6
IK7
IK8
Exon 1
2
3
4
5
6
7
Figure 2: Ikaros isoforms Ikaros expresses seven exons and has six ZNF domains, four
at the amino terminal and two at the carboxy terminal. Ikaros loses function when amino
terminal ZNF domains are lost. There are 11 Ikaros isoforms that have been found in patient
samples.
Ikaros can act as both a transcriptional activator and repressor (31, 32), but is
predominately a transcriptional repressor in lymphoid cells. Ikaros localizes to pericentromeric
heterochromatin where it is able to affect transcription by recruiting activators or repressors to
regulatory elements of DNA.
Ikaros target genes include many genes involved in hematopoiesis (33). Ikaros is able
to modulate the expression of other Ikaros family proteins, like Helios and Aiolos (34). Ikaros
may be responsible for commitment to the lymphoid lineage because of its role in activation of
expression of lymphoid-specific genes like Flt3, IL-7 and Rag1 (35). In T-cells, Ikaros also
regulates expression of other lymphoid-specific genes like L-selectin (36), IL-10 (37) and
interferon-γ (38). Ikaros also modulates expression of other transcription factors: activating
STAT4 (39) and repressing T-bet (38, 40). These targets highlight the role of Ikaros in immune
function and T-cell development.
Notch and Ikaros have been shown to interact in murine cells. In a cell line derived
from an Ikaros null mouse, Ikaros was shown to directly repress both Hes1 (25) and Deltex1
expression at the transcriptional level. Interestingly, ectopic expression of Ikaros in this cell line
increased CSL binding to the Hes1 promoter region, suggesting that Ikaros and CSL
cooperatively bind (26). In developing murine thymocytes, Ikaros represses expression of
Notch targets including Hes1, Deltex1, pTα, Gata3 and Runx1 (41).
6

Ikaros was established as a tumor suppressor after a series of studies in mice with
Ikaros dysfunction. A homozygous Ikaros null mouse was found to have a virtual absence of
lymphocytes and NK cells and clonal expansion of thymocyte precursors (42). Like the Ikaros
null mice, mice homozygous for a germline mutation in the Ikaros DNA-binding domain also
lack lymphocytes. However, these mice have normal myeloid and erythroid cells, suggesting
that Ikaros is required for development of lymphoid cells (43). Another mouse model with a
lacZ insertion causing limited Ikaros activity was shown to alter development of myeloid cells
(44). Ikaros plastic, an Ikaros mutant with a single base pair substitution in ZNF3 that reduces
DNA-binding ability while maintaining most other functions, is lethal in utero when
homozygous due to absent lymphopoiesis and results in defective lymphocyte differentiation
when heterozygous (45). These findings demonstrate the essential role of Ikaros in
lymphocyte survival and normal immune function.
Ikaros in T-cell Leukemia
Ikaros functions as a tumor suppressor in T-cells. Ikaros function may be lost through
deletion, expression of dn Ikaros isoforms, abnormal localization, or modifications like
phosphorylation. Loss of Ikaros function through deletion of Ikaros occurs in about 5% of TALL patients (46-48). The dn Ikaros isoform IK6 was found to compose 22.2% of the total
expression of the IKZF1 gene in a study of 79 adult T-ALL patient samples (49). In human TALL, Ikaros binds DNA most strongly during the G1 phase of the cell cycle, but
phosphorylation of Ikaros by casein kinase 2 (CK2) attenuates DNA-binding to the upstream
regulatory elements (URE) during S phase (50, 51). During S phase, Ikaros binds with high
affinity to pericentromeric heterochromatin in human T-ALL, whereas it is diffusely distributed
throughout the nucleus during S phase in murine models. This difference in localization
suggests that Ikaros function in human cells is distinct from its function in murine cells (50).
The prognostic significance of the loss of Ikaros function in human T-ALL has not been
evaluated.
Notch and Ikaros in Leukemia and Lymphoma
Aberrant Notch signaling and expression of truncated Ikaros isoforms have been
shown in T-ALL. Ikaros has been shown to inhibit downstream Notch signaling by a variety of
mechanisms. Specifically, Ikaros interferes with formation of the Notch:CSL complex (24), and
also represses Notch signaling by binding to the UREs of the Hes1 (25), pTα and Deltex1
promoter regions (26). Additionally, Notch signaling has been shown to alter Ikaros isoform
expression in murine T-ALL. These findings necessitate further investigation into the
relationship between Notch signaling and Ikaros isoform expression in human T-ALL.
7

In a proviral insertional mutagenesis study in transgenic mice expressing constitutive
ICN1, a frequent Moloney murine leukemia virus (MLV) insertion site was the IKZF1 gene (24).
These mutant mice expressed a decreased level of IK1 and IK2 but an increased level of nonfunctional or non-DNA-binding Ikaros isoforms. It was suggested that these mice experienced
a more rapid onset of T-cell leukemia due to the inability of Ikaros to repress the activated
Notch target genes (24). Another study revealed that γ-radiation-induced lymphomas in mice
expressed increased Notch1 mRNA, decreased Notch2 mRNA and a partially inactivated
Ikaros isoform (52). In a similar study, Dumortier et al. demonstrated that a hypomorphic
mutation of Ikaros causes thymic T-cell lymphomas in 100% of mice. These tumors, with
reduced Ikaros activity, have strong Notch activation, specifically increased Notch3 and pTα
expression. Furthermore, reintroduction of Ikaros was shown to decrease expression of Notch
target genes and to decrease proliferation. In a ChIP assay, Ikaros was shown to bind and
repress the Hes1 promoter (22). In summary, the cooperation between Ikaros inactivation and
Notch activation promotes murine T-cell leukemias and lymphomas.
In terms of mechanism, Kathrein et al. demonstrated that CSL represses Hes1 more
effectively in the presence of Ikaros in a murine T-cell leukemia line, JE131, due to
cooperative DNA binding of Ikaros and CSL. More specifically, chromatin immunoprecipiation
revealed that CSL and Ikaros bind DNA in the Hes1 and Deltex1 promoter regions
simultaneously and that CSL binding increases in the presence of Ikaros (26). However, other
studies in immature murine thymocytes have argued for competitive DNA binding of Ikaros
and CSL instead of cooperative DNA binding (22, 24, 25). In an electromobility shift assay, it
was demonstrated that Ikaros and CSL binding to the Hes1 regulatory elements in DN4
murine T-cells is mutually exclusive (25). In summary, Ikaros and CSL bind to the same
consensus sequence of DNA, but their interaction may be determined by the cell type and
context.
Another way in which Ikaros has been shown to repress Notch signaling is through
chromatin remodeling. Ikaros binds regions in the Notch1 promoter and blocks transcriptional
activity by associating with repressors like HDACs. When Ikaros is lost, the now permissive
chromatin structure allows transcription of Notch1, especially at alternative promoters resulting
in ligand-independent Notch signaling (53, 54). It has also been suggested that Ikaros exerts
its repressive effect on Notch targets by forming complexes with CSL (55) or associating with
ICN1 (56).
Taken together these studies demonstrate that there is a reciprocal interaction
between Ikaros and Notch pathways in murine T cell malignancies, whereby loss of Ikaros
aids in the expression Notch downstream genes, effectively increasing Notch signaling and
8

promoting T cell transformation and leukemia growth and survival in mice. The focus of my
work is to determine whether these mechanisms are relevant in human T cell leukemia.
Hypothesis
Interactions between Notch and Ikaros pathways alter the growth of human T-ALL, with
disruption of Ikaros favoring growth of T-ALL through de-repression of Notch signaling.
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CHAPTER 2. Effect of Notch activation on Ikaros isoform expression
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Rationale
Bellavia et al., have shown that constitutive Notch3 activation promotes the expression
of dominant-negative, non-DNA-binding Ikaros isoforms in the pre-malignant and malignant
thymocytes and lymph node cells in an ICN3 transgenic mouse model, shown in Figure 3.
They suggest that this shift in Ikaros isoform expression pattern is due to upregulation of HuD,
an RNA splicing protein, and is dependent on expression of pTα, a regulator of T-cell
development. In other words, Notch activation via ICN3 upregulates pTα, and in turn
upregulates HuD. Increased HuD activity was correlated to increased expression of dominantnegative Ikaros isoforms (57). As described in the introduction, Bellavia demonstrated in ICN3
transgenic mice that upregulation of HuD splicing protein led to expression of truncated Ikaros
isoforms, allowing for enhanced Notch signaling. They demonstrated in a single human cell
line that Notch3 similarly induced truncated Ikaros isoform expression. Based on the work from
this group, we hypothesized that Ikaros isoform expression is similarly regulated by Notch
signaling in human T-ALL. Therefore, the ability of Notch signaling to regulate Ikaros isoform
expression was studied in human T-ALL in vitro in order to determine whether activation of
Notch signaling inhibits Ikaros function by promoting expression of dominant negative Ikaros
isoforms at the expense of wild-type Ikaros isoforms.
Figure 3: Shift to dn Ikaros in murine
thymocytes with constitutive ICN3 expression
This research was originally published in EMBO J.
Bellavia, D., Mecarozzi, M., Campese, AF.,
Grazioli, P., Talora, C., Frati, L., Gulino, A.,
Screpanti, I. "Notch3 and the Notch3-upregulated
RNA-binding protein HuD regulate Ikaros
alternative splicing." EMBO J. 2007; 26(6): 167080. © John Wiley & Sons, Inc.

Approach
Because constitutive Notch3 activation in a transgenic mouse model has been shown
to increase expression of dominant-negative Ikaros isoforms in premalignant and malignant
thymocytes and lymph node cells (57), we tested whether Notch activation altered Ikaros
isoform expression in human T-ALLs. To determine the effect of individual Notch receptor
activation on Ikaros isoform expression, T-ALL cell lines were transduced with one of the four
Notch receptor homologs, ICN1-4. The ICN constructs are in a MigR1 vector with a GFP tag
11

that is regulated by an internal ribosome entry site (IRES). Notch activation was verified both
by flow cytometric analysis of GFP expression and by immunoblotting for the Notch target
gene Hes1. In addition to Hes1, blots were probed with an antibody to Ikaros to reveal any
changes in Ikaros isoform expression.
Results
To evaluate the expression and localization of Ikaros isoforms in human T-ALL, we
performed immunoblotting of T-ALL cell lines and found that Ikaros was expressed in the
nucleus in all lines, at relatively similar levels. In Jurkat and Molt4 cells, the predominate Ikaros
isoform was IK1, the wild-type, repressor form of Ikaros (Figure 4). There were between 2 and
7 dominant-negative isoforms seen depending on the length of blot exposure. As expected,
the Notch target gene Hes1 was seen in the nucleus.

Ikaros

Figure 4: Ikaros localized to the nucleus in
nuclear

cytoplasm

lysate

Molt4
nuclear

cytoplasm

lysate

Jurkat

Jurkat and Molt4 cells Jurkat and Molt4 cells
were collected and either whole cell lysates were
prepared or fractionation was performed. The
lysates or fractions were then subjected to SDSPAGE followed by immunoblotting.

Hes1
β-actin
Potent Notch activation via transduction of constitutively active forms of all four Notch
receptors (ICN1-4) into Jurkat cells induced upregulation of Hes1 compared to the GFP-only
control cells, indicating Notch activation. Despite the activation of Notch signaling, even with
the Notch3 isoform ICN3, Jurkat cells maintain predominantly WT Ikaros expression and show
no increase in expression of dn Ikaros isoforms compared to the GFP control cells (Figure 5).
These experiments were carried out up to 40 days, with no changes in Ikaros isoform
expression.
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Figure 5: Ikaros expression is unchanged by Notch activation in Jurkat cells Jurkat
cells were transduced with GFP-tagged ICN1, 2, 3, or 4 retrovirus. Cells were analyzed for
GFP expression prior to lysis.
Similar to Jurkat cells, ectopic expression of ICN1-4 in SupT1 T-ALL cells did not
increase the expression of dominant-negative Ikaros isoforms, indeed in SupT1 cells the levels
of dominant-negative isoforms appears to decrease modestly across all ICN1-4, compared to
GFP-only controls. Importantly SupT1 cells have high endogenous Notch activation due to
presence of the t(7;9), which produces the constitutively-active isoforms of Notch1, As such
SupT1 cells transduced with ICN1-4 do not show further upregulation of Hes1 (Figure 6).
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GAPDH
Figure 6: Ikaros expression unchanged by Notch activation in SupT1 cells SupT1
cells were transduced with activated Notch isoforms, ICN1-4, and analyzed for GFP
expression by flow cytometry. Cell lysates were prepared and analyzed by immunoblotting
for Hes1 and Ikaros.
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Notch activation, via transduction with activated Notch receptors ICN1-4, does not
increase expression of truncated Ikaros isoforms in two human T-ALL cell lines: Jurkat and
SupT1.
Summary and Discussion
In this chapter, the ability of Notch signaling to affect Ikaros isoform expression in
human T-ALL in vitro was evaluated. Human T-ALL cell lines were transduced with activated
Notch receptors, ICN1-4 but no shift in Ikaros isoform expression from wild-type to dominantnegative was observed in contrast to the findings of Bellavia et al. In fact, diminished
expression of truncated Ikaros isoforms was observed in SupT1 cells, a line with potent
constitutive Notch signaling. These results suggest that Notch activation does not universally
increase dn Ikaros isoform expression in human T-ALL, and raises the possibility that strong
Notch activation may actually decrease dn Ikaros isoform expression, as seen in the SupT1
line. This observation clearly needs to be tested in a larger panel of T-ALL, and preferably in
primary T-ALL cells with different Notch pathway activation status.
The observations may be explained by differences between murine and human cells,
like the expression of IKH, an isoform unique to humans. This hypothesis could be tested by
repeating the experiments in murine T-ALL cell lines. If a shift is observed in the murine cells
but not the human cells, then it would be reasonable to conclude that Notch regulates Ikaros
isoform expression in murine but not human cells because of the inherent differences between
the cellular machinery in the two species. However, if no shift was observed in the murine TALL cells, then the differences between the species is not a sufficient explanation and another
hypothesis could be tested.
Another explanation for the lack of effect is the possibility that murine Notch3
activation, but not human Notch3 activation, upregulates HuD. To test this hypothesis, the
experiments should be repeated using both murine and human T-ALL cell lines and the blots
probed for HuD, in addition to Hes1 and Ikaros. If HuD is upregulated in the murine cells but
not the human cells, then the reasonable conclusion is that Notch3 activation in human T-ALLs
does not alter Ikaros isoform expression because the RNA splicing protein is not upregulated.
It is also possible that HuD is upregulated in both cell types, but this upregulation does not
result in increased expression of truncated Ikaros isoforms in human cells.
One other possible explanation is that Notch activation is only able to modulate Ikaros
isoform expression in non-malignant and/or immature thymocytes, prior to cell transformation.
Levels of Notch1 vary during T-cell development and Ikaros regulates genes responsible for Tcell differentiation (58, 59). These data suggest that the Notch:Ikaros environment may
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determine the ability of Notch to regulate Ikaros isoform expression. To test this hypothesis,
these experiments could be repeated in normal thymocytes and lymphoid progenitor cells from
both mice and humans.
The observation that potent Notch activation in the Notch1-translocated SupT1 cell line
appears to decrease dn Ikaros isoform expression may represent a negative feedback loop,
since we would anticipate this would impair Notch signaling, as described in the next chapter.
In conclusion, Notch activation via ectopic expression of ICN1-4 does not appear
increase the expression of truncated Ikaros isoforms in the human T-ALL lines tested
suggesting that the mechanism of the shift in isoform expression pattern is dependent upon
signaling pathways not active in all human T-ALL cells.
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CHAPTER 3. Notch signaling inhibited by IK1
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Rationale
In murine T-ALL, IK1 inhibits Notch signaling. Specifically, Ikaros interferes with
formation of the Notch:CSL complex (24), and also represses Notch signaling by binding to the
upstream regulatory elements of the Hes1 (25), pTα and Deltex1 promoter regions (26).
Because of the differences between human and mouse Notch and Ikaros signaling, it is
important to establish that the effects of Ikaros on Notch signaling observed in murine T-ALL
models are valid in human T-ALL models.
Approach
First, western blots to measure endogenous Ikaros expression were performed in the
three human T-ALLs (Figure 7). Then, to determine the effect of Ikaros expression on the
growth and survival of T-ALL, competitive proliferation assays were performed. In these
assays, cells were transduced and monitored for GFP expression. Then, the effect of Ikaros
on Notch target genes was measured using a HES reporter assay and PCR.
Results
Jurkat Molt4 SupT1
Figure 7: Endogenous Ikaros expression Jurkat,
Ikaros

Molt4, and SupT1 cells were collected and lysed. After
protein quantification, SDS-PAGE was performed on the
lysates, followed by immunoblotting.

β-actin

Effects of IK1 on growth and survival
In this chapter, we explore the phenotypic effects of Ikaros on Notch signaling in
human T-ALLs. First, the effect of ectopic expression of dnMAM on cell proliferation and
survival in three T-ALL cell lines was evaluated in competitive proliferation assays (Figure 8A).
Next, the effect of ectopic expression of IK1 on cell proliferation and survival was evaluated. In
Jurkat cells, the GFP control cells outcompeted the IK1 expressing cells by 42% in the 16 days
following transduction (Figure 8B). A western blot for Ikaros was performed four days after
transduction, the day of highest GFP expression. This blot shows an increase in IK1
expression, as well as an increase in expression of other Ikaros isoforms.
In Molt4 cells, the GFP control cells outcompeted the IK1 expressing cells by 72% in
the 16 days following transduction (Figure 8B).
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In SupT1 cells, the GFP control cells outcompeted the IK1 expressing cells by 92% in
the 18 days following transduction (Figure 8B). A western blot for Ikaros was performed four
days after transduction, the day of highest GFP expression and shows an increase in IK1
expression, as well as an increase in expression of other Ikaros isoforms.
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Figure 8: Growth of Jurkat, Molt4, and SupT1 cells inhibited by ectopic expression of
IK1 T-ALL cells were transduced with GFP-tagged Ikaros1 or GFP-tagged empty vector.
(A, B) Competitive proliferation assays in which cells were analyzed by flow cytometry for
percent GFP positivity and normalized to the day of maximal GFP expression. (B)
Immunoblot probed for cleaved Notch, Hes1, and β-actin as a control.
Ectopic expression of IK1 inhibits growth and proliferation of three human T-ALL cell
lines. Interestingly, the cell line with the strongest Notch activation due to the t(7;9)
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translocation is the most sensitive to overexpession of IK1. Molt4, the cell line with moderate
Notch activation, is intermediately sensitive to Ikaros expression. Jurkat, with the lowest level
of Notch activation, is the cell line that is the least sensitive to Ikaros expression. Because of
this correlation between level of endogenous Notch activity and sensitivity to Ikaros expression
as well as the similarity to the effect of dnMAM, it was hypothesized that the inhibition of
growth and proliferation resulted from an inhibition of Notch signaling. Therefore, a series of
luciferase assays was conducted to evaluate the effect of IK1 expression on Notch signaling.
Effects of IK1 on a Hes reporter construct
HesAB

5’-TGAAAGTTACTGTGGGAAAGAAAGTTTGGGAAGTTTCACACGA-3’
CSL

HesΔAB

CSL

5’-TGAAAGTTACTG.…………………..…………...AAGTTTCACACGA-3’

Figure 9: HES reporter constructs The HesAB reporter construct is a 40 base pair portion
of the Hes1 promoter region and the HesΔAB reporter construct is similar but lacks the two
CSL-binding sites.
The luciferase reporter, HesAB, is a 40 base pair region of the Hes1 promoter with two
CSL binding sites, making this reporter sensitive to canonical Notch signaling. The Hes∆AB
reporter is similar to the HesAB reporter, but has a 15 base pair deletion that eliminates the
CSL binding sites and thus is insensitive to canonical Notch signaling (Figure 9). To show that
the HesAB reporter is sensitive to Notch signaling, 293T cells were transfected with ICN1, and
the reporter activity increased, as expected (Figure 10A). Similarly, IK1 has a dose-dependent
repressive effect on the HesAB reporter (Figure 10B).
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Figure 10: Dose-dependent changes in CSL reporter activity by ICN1 and IK1 (A)
293T cells were transfected with either empty vector control (MigR1) or increasing amounts
of ICN1, along with the luciferase reporter and Renilla control. (B) 293T cells were
transfected with either empty vector control (MigR1) or increasing amounts of IK1, along
with the luciferase reporter and Renilla control.
The CSL luciferase reporter activity increases with increasing amounts of ICN1
transfected into the cells. Increasing amounts of IK1 exert an increasingly repressive effect on
the CSL luciferase reporter.
IK1 functions as a repressor of canonical Notch signaling and is able to bind CSL
binding sites in the 40 base pair region of the Hes1 promoter. Interestingly, IK1 retains the
ability to decrease CSL reporter activity with the Hes∆AB reporter (Figure 11A), suggesting
that it also binds non-CSL binding sites in the Hes1 promoter to exert its repressive effect. The
HesAB luciferase reporter activity is increased by ICN1 expression and inhibited by IK1
expression. The Hes∆AB luciferase reporter activity is not significantly increased by ICN1
expression, but is significantly inhibited by IK1 expression (Figure 11A). IK1 inhibits ICN1
reporter activity, suggesting competitive binding to HesAB (Figure 11B).
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Based on these assays, Ikaros inhibits cell growth and exerts a repressive effect on a
CSL reporter. To further evaluate the inhibition of Notch signaling, qRT-PCR for Notch target
genes Hes1 and Hes5 was performed. Expression of either IK1 or dnMAM represses Hes1
expression, both by approximately 90% (Figure 12A). Expression of IK1 also represses Hes5
expression by approximately 50% (Figure 12B). These results, showing downregulation at the
transcriptional level of Hes1 and Hes5, are consistent with the hypothesis that Ikaros inhibits
cell growth via inhibition of Notch signaling in human T-ALL.
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Figure 12: IK1 represses expression of Hes1 and Hes5 at the transcriptional level
Jurkat cells were transduced with empty vector control, IK1 or dnMAM virus and sorted to
select the cells expressing the highest levels of GFP three days after transduction. RNA
was extracted using the Qiagen RNeasy kit and cDNA was prepared using the Qiagen
Omniscript kit. cDNA from the transduced cells was analyzed by qRT-PCR for Notch target
genes. (A) Hes1 transcription is downregulated by approximately 90% in cells that
ectopically express either IK1 or dnMAM. (B) Hes5 transcription is downregulated by
approximately 50% in cells that ectopically express IK1.
Summary and Discussion
In this chapter, Ikaros expression was shown to inhibit cell growth and proliferation and
this inhibition may be Notch-dependent. Competitive proliferation assays illustrate the
inhibitory effect of IK1 expression on T-ALL growth and proliferation. Interestingly, the level of
Notch signaling in each cell line is correlated to its susceptibility to IK1 expression.
Endogenous Notch signaling is strongest in SupT1, intermediate in Molt4 and lowest in Jurkat.
Similarly, SupT1 growth and proliferation was inhibited most strongly, and Jurkat growth and
proliferation was the least inhibited. This correlation suggests IK1 mediates its effects on cell
growth and proliferation through inhibition of Notch signaling.
Based on the hypothesis that IK1 inhibits growth and proliferation of human T-ALL by
inhibition of Notch signaling, luciferase assays using a CSL reporter construct were performed.
In these assays, the CSL reporter activity increased with increasing ICN1 expression and
activity decreased with increasing IK1 expression, as hypothesized. CSL reporter activity
reached a maximum of a 5-fold increase resulting from ICN1 expression. ICN1 was also able
to increase the reporter activity by approximately 65% with the mutant CSL reporter, HesΔAB.
This modest effect may be due to residual binding activity of ICN1 to HesΔAB and could be
tested by using a different Hes1 promoter reporter construct. Additionally, CSL reporter activity
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decreased 3-fold with IK1 expression. Unexpectedly, IK1 was also able to repress the mutant
CSL reporter, HesΔAB, to the same degree as HesAB. This preserved repression of the CSL
reporter may be due to Hes-independent Ikaros activity or promiscuous binding to similar sites
in the HesΔAB reporter construct. Interestingly, while both Ikaros and CSL bind the TGGGAA
sequence found at four sites (A, B, C, D) in the Hes1 promoter (7), Ikaros prefers to bind site B
while CSL prefers site A (25). The luciferase assays that demonstrate the ability of Ikaros to
bind the HesAB reporter construct prompted the following qRT-PCR experiments that reveal
inhibition of transcription of Notch target genes by IK1.
qRT-PCR demonstrates that IK1 expression downregulates two Notch target genes,
Hes1 and Hes5, at the transcriptional level. Interestingly, both IK1 and dnMAM were shown to
repress Hes1 by 90%. This equivalent repression may result from Notch-independent
repression by Ikaros or from inhibition via the same mechanism. If IK1 and dnMAM repress
Hes1 via the same mechanism, expression of both IK1 and dnMAM would repress Hes1
expression similarly to either IK1 alone or dnMAM alone. The 90% repression of Hes1 by IK1
suggests that Hes1 expression is primarily Notch-mediated in human T-ALL. These findings
are consistent with the literature that explores the inhibitory effect of Ikaros on Notch signaling
in murine cells, both in vivo and in vitro. These findings also are consistent with the hypothesis
that Ikaros inhibits Notch signaling in human T-ALL.
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CHAPTER 4. Discussion
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The work presented in this thesis illuminates the effects of the interactions between
Notch signaling and Ikaros on human T-ALL growth and proliferation. The literature suggests
that the interaction between Notch and Ikaros plays an important role in leukemogenesis, and
that loss of Ikaros may have prognostic significance in T-ALL. However, the key experiments
that describe these Notch:Ikaros interactions used murine cells. Many differences between the
Notch and Ikaros pathways in murine and human cells have been described. Because of these
differences, it was important to establish whether the effects seen in murine cells are also
seen in human cells. The data in this thesis describes the effects of Notch activation on levels
of Ikaros isoform expression in human T-ALL and describes the effects of Ikaros expression
on Notch signaling in human T-ALL cell lines.
Expression of activated Notch receptors in human T-ALLs does not increase
expression of dominant-negative Ikaros isoforms
Constitutive Notch signaling via ICN3 in a transgenic mouse model and in a murine cell
line was shown to upregulate expression of dominant-negative Ikaros isoforms (57). Based on
this finding, we hypothesized that Notch signaling regulates Ikaros isoform expression in
human T-ALL. However, the data is not consistent with this hypothesis, and there are a
number of explanations for the differences observed between the murine and human cells.
Ikaros isoform expression and Ikaros function in mice are different from those in
humans. Humans uniquely express the Ikaros isoform IK-H, that has been shown to alter
function of other Ikaros isoforms (30). The differences in endogenous Ikaros expression
between human and murine cells may account for the differences seen upon Notch activation.
Additionally, it has been shown in humans that the Ikaros isoform expression profile in normal
cells is different than that of malignant cells (30), Ikaros expression peaks at the DN4 stage of
thymocyte development (25) and Ikaros levels vary throughout myeloid differentiation (44).
Furthermore, levels of endogenous Notch signaling, pTα expression, and HuD expression vary
during differentiation (60). Notch activation via constitutive ICN3 expression begins in utero
(57). Because of these differences, Notch activation may be able to alter the Ikaros isoform
expression profile in normal, non-malignant cells, but not in malignant cells. The changes in
Ikaros isoform expression were observed first in two-week old mice. Notch activation early in
development of the thymocytes and lymph node cells changed the Ikaros isoform expression
pattern and the changes were maintained until at least six weeks (57). These data suggest
that Notch activation must occur early in lymphoid cell development and differentiation in order
to change the Ikaros isoform expression pattern. This hypothesis could be tested by activating
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Notch in normal, non-malignant T-cell and also in common lymphoid progenitor cells and
examining the Ikaros isoform expression profile by immunoblotting.
Another explanation for consistent Ikaros isoform expression in the presence of
overexpression of ICN3 is that Notch activation via constitutive Notch3 expression in a
transgenic mouse model affects the cells differently than ectopic overexpression of ICN. For
example, the unique level of Notch activation in the transgenic mouse model may only affect
some Notch target genes and not others. It is possible that HuD is only responsive to the type
and level of Notch activation in the transgenic mouse model. Interestingly, another group
showed that the level of HuD expression was unaffected by Ikaros overexpression in a murine
leukemia cell line derived from an Ikaros null mouse (41).
It is also possible that HuD functions differently in human cells than in mouse cells.
Firstly, Notch activation may be sufficient to upregulate HuD in murine cells but not human
cells. This hypothesis could be tested by activating Notch in a panel of both murine and human
cell lines and then immunoblotting for HuD expression. If HuD is not upregulated in human
cells, then it is reasonable to conclude that the Ikaros isoform expression profile is not altered
in human T-ALL cells upon Notch activation because HuD is not upregulated. However, if HuD
is upregulated in both cells types, then it is reasonable to conclude that HuD is not responsible
for increased expression of truncated Ikaros isoforms in human T-ALL cell lines. To confirm
this hypothesis, immunoblotting for Ikaros in cells that ectopically overexpress HuD would be
performed. If HuD promotes expression of truncated Ikaros isoforms, then an increase would
be observed in the HuD overexpressing cells. If another protein or mechanism is responsible,
then no difference would be observed.
Lastly, limitations of the experimental design may account for the consistent Ikaros
isoform expression in human T-ALL cell lines that overexpress ICN3. Notch activation was
confirmed through upregulation of Hes1. Jurkat and Molt4 cells lines showed upregulation of
Hes1 when overexpressing ICN, however the Hes1 levels were unchanged in SupT1 cells.
Because Notch was only activated in two of the cell lines, a Notch or Hes1 knock down
experiment may confirm that Ikaros isoform expression is not regulated by Notch in human TALL. For example, this hypothesis would be upheld if a knock down of Notch in SupT1 cells
had no effect on Ikaros isoform expression. However, if a knock down of Notch in SupT1 led to
decreased expression of truncated Ikaros isoforms, then the hypothesis that Notch regulates
Ikaros isoform expression in human T-ALL would be supported. Lastly, ectopic overexpression
of ICN may not activate Notch at physiologically relevant levels. In order to test another mode
of Notch activation, physiological levels of Notch activation would be better reproduced in an
experiment using plate-bound Notch ligand or co-culture.
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IK1 inhibits growth and proliferation and represses Notch signaling in human T-ALL
Ikaros loses its ability to inhibit Notch signaling in murine thymocytes and T-ALL
through a number of proposed mechanisms such as deletion, expression of dn Ikaros
isoforms, aberrant localization and phosphorylation. However, most of these effects have not
been demonstrated and these mechanisms have not been explored in human cells. Therefore,
it was our goal to determine the effects of Ikaros expression on Notch signaling in human TALL.
The three cell lines used in these experiments were chosen based on their levels of
endogenous Notch signaling. Jurkat cells express Notch1 receptors that have WT HD and
PEST domains and relatively low levels of Notch activation. Molt4 cells express Notch1
receptors with mutations in the HD, PEST and PTEN domains, resulting in moderate Notch
activation. SupT1 cells possess the t(7;9) translocation that fuses the TCRβ and Notch1
genes, resulting in strong Notch activation, independent of ligand binding (61).
Competitive proliferation assays reveal that ectopic expression of IK1 inhibits growth
and proliferation to varying degrees correlated to level of endogenous Notch signaling in each
T-ALL cell line. A similar effect is seen when Notch signaling is inhibited by other methods,
including dnMAM (62), a dnMAM-derived peptide called SAHM1 (61), and pharmacological
inhibition (62).
The competitive proliferation assays reveal the growth inhibition of IK1 transduced
cells, but the experiment has its limitations. For example, IK1 overexpression of the long
terminal repeats of the retroviral vector also results in expression of shorter Ikaros isoforms.
To verify that IK1 and not the shorter isoforms is responsible for the growth inhibition, a
competitive proliferation assay with an IK1 knock out could be performed. IK1 knock out would
provide a competitive advantage, stimulate growth, and induce expression of Notch target
genes if IK1 is primarily responsible for the growth inhibition observed in the competitive
proliferation assays. Additionally, another competitive proliferation assay could be performed
to determine the effect of shorter isoforms on IK1 activity. Cotransduction with IK1 and IK6
may provide a partial rescue of the IK1 inhibitory effect because IK6 may interfere with normal
IK1 function.
It was hypothesized that IK1 mediates its effect primarily through inhibition of Notch
signaling because IK1 has a similar growth inhibitory effect on human T-ALL cell lines as
dnMAM (62). Therefore, a series of CSL luciferase reporter assays were performed to
demonstrate the ability of IK1 to inhibit Notch signaling. As hypothesized, ICN1 overexpression
increases reporter activity in a dose-dependent manner, and similarly IK1 overexpression
decreased reporter activity in a dose-dependent manner.
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These experiments could be improved by using T-ALL cell lines instead of HEK293T
cells. HEK293T cells were chosen because of their lack of endogenous Ikaros expression,
minimal Notch activity, and transfection efficiency. These experiments, if repeated in T-ALL
cell lines, would shed light on the effects of endogenous Notch and Ikaros activity on the CSL
reporter. Additionally, reporter activity may be increased when ICN1 is transfected along with
other Notch transcriptional complex components like Mastermind and CSL.
Both ICN1 and IK1 were shown to affect the HesAB reporter construct, but only IK1
maintained its effect when the HesΔAB reporter was used. ICN1 increased the CSL reporter
activity half as effectively with HesΔAB as with HesAB. This increase may be due to residual
binding activity of ICN1 to the HesΔAB reporter construct. Use of another HesAB reporter with
different mutations could test this hypothesis. Interestingly, IK1 expression decreased CSL
reporter activity by approximately 70%, regardless of the CSL reporter used. These results
suggest that while IK1 and ICN1 bind 5’-TGGGAA-3’, IK1 may bind more permissively or have
a higher affinity for the flanking sequence than ICN1.
IK1 was shown to have a repressive effect on Notch signaling in the luciferase assays.
Therefore, qRT-PCR for Notch target genes Hes1 and Hes5 was performed. As Figure 14A
shows, both IK1 and dnMAM repress Hes1 transcription by approximately 90%. This strong
repression by dnMAM suggests that Hes1 expression is predominately controlled by Notch
signaling in human T-ALL. The equivalent repression by IK1 and dnMAM suggests that either
IK1 repression is Notch-independent or that IK1 and dnMAM repress Notch through the same
mechanism. Based on the luciferase assays, it is unlikely that IK1 repression of Hes1
transcription is Notch-independent. To test whether IK1 and dnMAM repress Notch signaling
through the same mechanism, qRT-PCR of IK1 and dnMAM cotransduced cells would be
performed. If both constructs repress through the same mechanism, then cotransduced cells
would not exhibit greater repression of Hes1. If IK1 and dnMAM repressed Hes1 expression
via different mechanisms, then co-transduced cells would likely exhibit greater repression of
Hes1 than singly transduced cells. To probe further the mechanism of repression, coimmunoprecipitation (coIP) and chromatin immunoprecipitation (ChIP) experiments could be
performed. CoIPs for dnMAM and CSL or IK1 and CSL would show if both dnMAM and IK1
similarly bind CSL. Progressively stringent salt washes following the IP would provide an
indication of binding affinity. ChIPs for either dnMAM or IK1 would reveal their similarities and
differences in chromatin binding, thus providing insight into their ability to regulate transcription
of target genes.
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A few hypotheses adequately explain the data presented in Chapter 3. First, it is
hypothesized that IK1 directly regulates Notch target gene expression by binding and
repressing Notch target gene regulatory elements, as they do in murine models. For example,
Chari et al. demonstrated that Ikaros, but not RBP-Jκ, is required for repression of the
following Notch target genes in DP murine thymocytes: Deltex1, Hes1, Runx1, Notch1, and
pTα (63). Another group showed that RBP-Jκ and Ikaros are able to bind the TGGGAA
sequence found in the Hes1 promoter region separately but not together in immature murine
thymocytes, suggesting RBP-Jκ and Ikaros compete for binding (25). Furthermore, dnMAM
and reintroduction of Ikaros to an Ikaros null leukemia cell line have similar repressive effects
on the following Notch targets: Hes1, Deltex1, pTα, Gata3, Runx1, Notch1, Notch3, NRARP
and CD25. Notch targets Hes1, Deltex1 and pTα are constitutively expressed in Ikarosdeficient leukemia cell lines (41). The hypothesis that IK1 directly represses transcription of
Notch target genes could be explored further using ChIP assays in human T-ALL.
A second hypothesis to explain the inhibition of Notch by Ikaros is that IK1 interferes
with Notch transcriptional complex formation, thus inhibiting transcription of Notch target
genes. CSL and Ikaros bind the same consensus sequence, suggesting that CSL and Ikaros
compete for binding to regulatory elements (24). However, in a murine leukemia cell line
derived from an Ikaros null mouse, Ikaros promoted binding of CSL to Hes1 regulatory
elements, suggesting that Ikaros and CSL are able to bind together (26). The hypothesis that
Ikaros competes with CSL for binding could be tested by ChIP assays.
A third explanation may be that Ikaros modulates the binding ability of transcription
factors by altering chromatin structure. Ikaros is functional when localized to pericentromeric
heterochromatin, and localization in human leukemia is cell cycle-dependent and regulated by
phosphorylation. During S phase, Ikaros is phosphorylated but is no longer able to bind
upstream regulatory elements of Ikaros target genes (50). Furthermore, it has been shown that
Ikaros phosphorylation alters its ability to bind DNA, to localize to pericentromeric
heterochromatin, and to progress through the cell cycle (59, 64, 65). Upon Ikaros binding to
the upstream regulatory elements of Hes1 and Deltex1, histone H3 acetylation decreases and
thus transcriptional activity decreases (26). Hes1 and Hes5 were downregulated by Ikaros
expression in human T-ALL, perhaps due to decreased acetylation of the upstream regulatory
elements (UREs) of Hes1 and Hes5. This hypothesis could be tested by performing a ChIP for
acetylated H3, followed by qRT-PCR on the ChIP DNA for Notch target genes. If, for example,
expression of Notch target genes decreased in the cells overexpressing Ikaros, then it would
be reasonable to conclude that Ikaros represses Notch target gene expression through
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chromatin acetylation. Similarly, an acetylation inhibitor could be used to determine is the
Hes1 and Hes5 downregulation was in fact due to Ikaros-associated deacteylation of UREs.
In conclusion, activation of Notch signaling results in a slight decrease of Ikaros
expression, and Ikaros has been shown to decrease growth and proliferation of human T-ALL,
likely in a Notch-dependent manner. These findings recapitulate the data from murine studies
and lay the groundwork for studies to reveal the mechanism of Notch inhibition of Ikaros
expression and Ikaros repression of Notch signaling.
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Conclusions
The following has been demonstrated:
1. Ectopic expression of activated Notch receptors in human T-ALL cell lines does not
promote expression of dominant-negative Ikaros isoforms, and may decrease these
isoforms in some lines.
2. Human T-ALL cell lines have different Ikaros isoform expression patterns. The cell
lines with greater levels of endogenous Notch activity express more truncated Ikaros
isoforms.
3. Ectopic expression of IK1 inhibits growth and proliferation of human T-ALL cell lines
proportional to the degree of endogenous Notch activity.
4. IK1 behaves as a repressor and is able to bind the Hes1 promoter region, with WT or
mutant CSL binding sites.
5. IK1 downregulates Hes1 and Hes5 at the transcriptional level in human T-ALL.
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Future Directions
1. Bellavia et al., demonstrated that constitutive expression of ICN3 in a transgenic mouse
model resulted in increased expression of dnIK isoforms in both premalignant and
malignant thymocytes and lymph node cells. It is unclear whether this shift in Ikaros
isoform expression occurs in human T-ALL as a result of the mechanism described by
Bellavia et al. Therefore, to determine if Notch activation in human T-ALLs increases
expression of the RNA splicing protein, HuD, qRT-PCR and immunoblotting for HuD would
be performed. It is hypothesized that levels of HuD expression would be unaffected by
expression of activated Notch receptors in human T-ALLs because no increase in
truncated Ikaros isoforms was detected.
2. To determine if the shift in Ikaros isoform expression from wild-type to dominant-negative
reported by Bellavia et al., can be induced by expression of activated Notch receptors in
human cells, the experiments in Chapter 2 could be repeated in normal mouse and human
thymocytes. It is hypothesized that Notch activation in normal murine thymocytes would
result in upregulation of HuD, and thus an increase in expression of dominant-negative
Ikaros isoforms. It is hypothesized that this effect is unique to murine cells, and that neither
upregulation of HuD nor a shift in Ikaros isoform expression would occur. If, however,
activation of Notch signaling in the human thymocytes did result in these changes, it would
be hypothesized that dysregulated Notch signaling mediates its oncogenic effect in a
specific cell type at a specific stage of differentiation. Additionally, if an effect was seen in
human cells, cell staining and flow cytometry could reveal at which stage of development
(CD4CD8 status) the thymocytes must be for dysregulated Notch signaling to alter the
Ikaros isoform expression pattern.
3. It has been demonstrated that overexpression of ICN may result in decreased expression
of Ikaros isoforms. To describe further the interaction between Notch signaling and Ikaros
in human T-ALL and highlight the physiological significance of the observed effect on
Ikaros isoform expression, immunoblotting for Ikaros of cell lines in which endogenous
Notch signaling is inhibited could be performed. For example, in a cell line with active
Notch signaling, like SupT1, a Hes1 knockdown could reveal if inhibition of Notch signaling
may decrease the level of expression of dn Ikaros isoforms. Knockdowns of other Notch
target genes followed by immunoblotting for Ikaros may reveal which Notch targets are
responsible for regulating Ikaros isoform expression.
4. In human B-ALL, Ikaros is a known tumor suppressor and is associated with poor
outcome. In human T-ALL, the prognostic significance of loss of Ikaros function has not
been evaluated. Therefore, to determine if the Ikaros isoform expression profile may
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correlate with patient outcome, western blot analysis of human T-ALL patient samples
could be performed. It is hypothesized that the patients expressing the highest amount of
WT Ikaros isoforms relative to the levels of DN Ikaros isoforms would be less likely to
relapse and have higher rates of overall survival.
5. The competitive proliferation assays reveal that ectopic expression of IK1 inhibits growth
and proliferation of human T-ALL. To increase the physiological relevance of this finding,
competitive proliferation assays could be performed with Ikaros knockout. It is
hypothesized that a decrease in WT Ikaros function would provide a proliferative
advantage. To determine if the hypothesized proliferative advantage is due to increased
Notch signaling, competitive proliferation assays could be performed using cells with both
Ikaros knockout and ectopic expression of Hes1. It is hypothesized that Ikaros knockout
combined with Hes1 overexpression would not differ significantly from either Ikaros
knockout or expression of Hes1 alone, if the main repressive effect of Ikaros operates
through Hes1. However, if Ikaros represses other Notch target genes that control cell
growth and proliferation, then there may be a decrease in growth and proliferation of these
cells with both Ikaros knockout and Hes1 expression.
6. To determine which Notch target genes are most affected by Ikaros, qRT-PCR for the
following Notch target genes would be performed in human T-ALLs transduced with IK1
and Ikaros knockout T-ALLs: pTα, deltex1. To determine if the level of endogenous Notch
signaling and Ikaros isoform expression affects transcription of Notch target genes, qRTPCR could be performed in multiple cell lines. It is hypothesized that Ikaros affects a few
Notch target genes involved in cell growth and differentiation, and that cell lines with strong
Notch activation have the greatest change in Notch target transcript level. Additionally,
immunoblotting for Notch target could be performed to determine if both transcript and
protein levels are affected in a similar manner.
7. Multiple studies have shown that Ikaros binds to the upstream regulatory elements of
Notch target genes in murine cells. However, it is unclear whether this binding occurs in
human cells. Therefore, to describe the mechanism through which Ikaros represses Notch
signaling in human T-ALL, ChIP could be performed. ChIP assays may reveal novel
binding sites in human cells.
8. Ikaros has been shown to inhibit Notch signaling and to modulate expression of certain
Notch target genes. It is hypothesized that the Notch transcriptional complex composition,
the presence of Ikaros isoforms specifically, alters the function of the complex. In order to
determine the components of the transcriptional complexes, endogenous Ikaros, CSL, and
ICN would each be immunoprecipitated from human T-ALL lysates and analyzed by SDS34

PAGE followed by mass spectrometry analysis to identify the components of each
complex.
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Cell Culture
Human T-ALL cell lines were grown in RPMI-1640 (Gibco) supplemented with 10%
fetal bovine serum (FBS), 1 mM penicillin-streptomycin, 1 mM non-essential amino acids, 1
mM L-glutamine and 10 mM HEPES. Cells were passaged as needed.
HEK293T and HEK293GP2 cells were grown in Dulbecco’s Modified Eagle Medium
(Gibco) supplemented with 10% FBS, 1 mM penicillin-streptomycin, 1 mM non-essential amino
acids, 1 mM L-glutamine and 10 mM HEPES. Cells were passaged as needed.
All cells were incubated at 37°C in 5% CO2 in a moisture-controlled environment,
unless otherwise noted.
RNA Isolation and cDNA synthesis
RNA was extracted from cells using the Qiagen RNeasy system. First, T-ALL cells
lines were maintained and 1x106 cells were collected and pelleted at 300xg for 5 minutes. The
supernatant was removed and cells were lysed with addition of 350µl buffer RLT. The lysate
was homogenized using the QIAshredder spin column. The homogenized lysate was
transferred to an RNeasy spin column in a 2ml collection tube and centrifuged at 8000xg for
15 seconds. The flow-through was discarded and then 700µl of buffer RW1 was added to the
RNeasy spin column and centrifuged for another 15 seconds at 8000xg. Next 500µl buffer
RPE was added to the spin column and centrifuged for another 15 seconds at 8000xg. The
flow-through was discarded, another 500µl buffer RPE added, and the spin column was
centrifuged for 2 minutes at 8000xg. The RNeasy spin column was then placed into a new
collection tube and centrifuged for 1 minute at 8000xg. Next, the RNeasy spin column was
placed in another new collection tube and 30ml of RNase free water added to the RNeasy spin
column membrane. The column was then spun at 8000xg for 1 minute. The RNA
concentration was determined using the 260nm/280nm ratio using the NanoDrop
spectrophotometer.
cDNA was synthesized using the Qiagen Omniscript system. First, a master mix was
prepared, on ice. For each well, the following components were added: 2 microliters 10x buffer
RT, 2 microliters dNTP mix, 2 microliters oligo-dT primer, 1 microliter RNase inhibitor, 1
microliter omniscript reverse transcriptase. For example, if there were nine well, then the
master mix would contain 18 microliters 10x buffer RT, 2 microliters dNTP mix, 18 microliters
oligo-dT primer, 9 microliters RNase inhibitor, 9 microliters omniscript reverse transcriptase.
Next, 8 microliters of the master mix was added to each well, and then 1 microgram of RNA
was added, and RNase free water added to each well so that each well had a final volume of
20 microliters. The plate is then incubated at 37°C for 60 minutes. The concentration of cDNA
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was determined using the 260/280 using the NanoDrop spectrophotometer, and RT-PCR was
conducted as described below.
qRT-PCR
qRT-PCR was performed using the BioRad iCycler iQ PCR Detection System (BioRad
Hercules, CA), and the data analyzed using the ΔΔCT method described by Livak (66). Using
the TaqMan Gene Expression Master Mix protocol, a master mix was prepared. For each
reaction, 10 microliters 2x TaqMan Gene Expression Master Mix, 1 microliter 20x TaqMan
Hes1 expression or GAPDH expression assay, and 100 nanograms cDNA in 9 microliters.
Then, 20 microliters of the master mix was added to each well of the PCR plate. The plate was
covered and placed in the iCycler on the following program: one cycle at 50°C for 2 minutes,
one cycle at 95°C for 10 minutes, 60 cycles at 95°C for 15 seconds and 60°C for 1 minute,
and then held at 4°C.
The data was then analyzed using the ΔΔCT method to give relative expression levels.
Briefly, ΔCT is calculated: ΔCTHes1= average Hes1 CT – average GAPDH CT. Then ΔΔCT is
calculated: ΔΔCT= ΔCT Hes1 – ΔCTcalibration. The relative change is determined by the following
calculation: 2-ΔΔCT.
Viral Production
Retrovirus was made using HEK293GP2 cells transfected with VSV-G, pcGP, and the
construct of interest (ICN1, ICN2, ICN3, ICN4, IK1, MigR1). On the day before transfection,
5.5x106 HEK293GP2 cells were plated. The next day when the cells had reached 70%
confluency, they were transfected using JetPEI (Polyplus Transfection, New York, NY),
according to the manufacturer’s instructions. Briefly, the jetPEI transfection reagent was
diluted in 150mM sodium chloride. The plasmid DNA was diluted to a final concentration of 1
microgram per microliter in 150mM sodium chloride. Then, the jetPEI solution was added to
the diluted plasmid DNA, vortexed, and incubated for 15 minutes. Then, this solution was
added to the cells and the cells were incubated at 34°C. Viral supernatant was then collected
at 48 and 72 hours after transfection. Viral supernatant was centrifuged at 2000 rpm for 15
minutes to pellet debris.
Viral Transduction
In each well of a six well plate, 1x106 cells were plated in a volume of 400 microliters.
Polybrene was added to the viral supernatant, collected as described in the previous section,
to produce a final concentration of 8 micrograms/microliter. To each well of the six well plate,
1.6 milliliters of virus with polybrene was added. The plates were then centrifuged at 2300 rpm
for 1.5 hours and incubated at 34°C. After four to six hours of incubation, two milliliters of fresh
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media was added. The cells were then incubated at 34°C. Starting two days after transduction,
cells were analyzed by flow cytometry for GFP expression. Cells were passaged as needed.
Plasmids
IK1 GFP was kindly given by Dr. Charles Mullighan (St. Jude Children’s Research
Hospital, Nashville, TN). The IK1 GFP, as well as ICN1 GFP, ICN2 GFP, ICN3 GFP, ICN4
GFP and the empty vector are in an MigR1 backbone. These plasmids express the construct
and GFP off bicistronic DNA, resulting in expression of the construct that correlates directly to
the level of GFP expression.
Competitive Proliferation Assays
Cells were transduced as described above. On alternating days starting two to three
days after transduction, cells were analyzed by flow cytometry for GFP expression using a
Becton Dickson FACS CaliburTM. Data was collected using the FACS _____ software. For
each population, 10000 cells were analyzed. The flow cytometery data was then analyzed
using FlowJo software. Nonviable cells were excluded from analysis and untransduced, nonGFP expressing cells were used as a negative control for gating purposes. The percentage of
GFP positive cells were recorded and monitored over time.
Luciferase Assays
Luciferase assays were performed in HEK293T cells using the Dual-Luciferase
Reporter Assay System (Promega, Madison, WI). On the day before transfection, 5.5x106
HEK293T cells were plated. The next day when the cells had reached 70% confluency, they
were transfected using JetPEI (Polyplus Transfection, New York, NY), according to the
manufacturer’s instructions, as described above. 48 hours after transfection, cell lysates were
prepared using the passive lysis buffer. Lysates were analyzed for luciferase and Renilla
reporter activity using the BioTek Synergy 2 Microplate reader (BioTek, Winooski, VT). Data
was analyzed and normalized to 1 using Microsoft Excel.
Immunoblotting
Cells were counted using a hemocytometer. Then, 107 were pelleted by centrifugation
at 1000 rpm for 3 minutes and washed with 10 milliliters of ice-cold PBS. One milliliter of icecold lysis buffer was added to disrupt the cells and release their contents. Whole cell lysates
were made using lysis buffer containing the following: 50 mM HEPES, 150 mM sodium
chloride, 1 mM ethylene glycol tetraacetic acid, 10mM sodium pyrophosphate, 100 mM sodium
fluoride, 1.5 mM magnesium chloride, 10% v/v glycerol and 1% v/v Triton X-100. Just prior to
lysis, protease inhibitor (Roche, catalog number 1-679-498) was added.
39

Nuclear extracts and cytoplasmic fractions were made using the Active Motif Nuclear
Extract Kit (Active Motif, Calsbad, California), according to the manufacturer’s instructions.
Briefly, 8.8x106 cells were collected and washed with phosphate buffered solution (PBS). Cells
were then resuspended in 1X Hypotonic Buffer and incubated for 15 minutes on ice. Then,
Detergent was added, vortexed for 10 seconds, and the cells were centrifuged. The
supernatant, or cytoplasmic fraction, was collected. The nuclear pellet was resuspended in
Complete Lysis Buffer and incubated for 30 minutes on ice. The nuclear fraction was then
collected.
Protein concentration was determined using the Thermo Scientific Pierce BCA Protein
Assay Kit (Pierce Biotechnology, Rockford, IL), according to the manufacturers instructions.
First, the bovine serum albumin (BSA) standards were prepared. Then, the working reagent
was prepared by making a 50:1 dilution of Reagent A:B. Then, 25 µl of each standard or
unknown cell lysate sample was pipetted into a microplate well, either in duplicate or triplicate.
Then, 200 µl working reagent was added, mixed thoroughly and incubated at 37°C for 30
minutes. After being allowed to cool, the BioTek Synergy 2 Microplate Reader (BioTek,
Winooski, VT) was used to read the absorbance at 562 nm and concentrations were
determined.
To prepare samples for electrophoresis, cellular lysate containing 40 micrograms of
protein was mixed with 4X Laemmli buffer, boiled for five minutes, and loaded onto a 10%
polyacrylamide gel. Using a Bio-Rad apparatus, the gel was run at 80 volts for three hours or
at 3 milliamps overnight. The proteins were then transferred to a PVDF membrane for
visualization with Ponceau Red followed by antibody detection.
Antibodies
The Ikaros antibody, sc-13039, from Santa Cruz Biotechnology is a rabbit polyclonal
antibody against amino acids 1-100 of human Ikaros. For western blotting, a concentration of
1:1000 in 5% milk was used. The secondary antibody used was ECL anti-rabbit IgG,
horseradish peroxidase linked whole antibody from donkey (GE Healthcare, product number
NA934V) and a concentration of 1:5000 was used. The Hes1 antibody was a rabbit polyclonal
antibody from Abcam, product number ab71559. The ICN1 antibody was a mouse monoclonal
antibody from Cell Signaling Technology, product number 4147. The HRP-tagged GAPDH
antibody used was from Abcam, product number ab9385 at a concentration of 1:2000 in 5%
BSA. The HRP-tagged β-actin antibody used was from Abcam, product number ab8226 at a
concentration of 1:5000.
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